Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
ipo
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
venture capital
3
×
biogen
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
deals
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
What
ipo
3
×
medicines
3
×
bio
covid
roundup
acquisitions
activity
announced
approvals
biogen
cancer
ceo
clamped
collabs
daniel
deal
delays
despite
developing
drug
economic
family
fast
fda
gilead
gilead’s
hardest
help
hit
hottest
hunters
including
introduce
isn’t
lot
month
new
oric’s
o’day
plans
Language
unset
Current search:
medicines
×
ipo
×
" venture capital "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer